GEN Exclusives

More »

GEN News Highlights

More »
Sep 26, 2006

Pericor Science Finds Advance in Thrombin Inhibitor Research

  • Pericor Science reported that an ex vivo study (pig coronary artery) demonstrated that the company’s new compound covalently attaches to the inner lumen of the coronary artery with uniform mural coverage and penetration and retains its therapeutic activity by binding to thrombin. Thrombin is an enzyme that plays a central role in the formation of blood clots and cell growth in the injured coronary artery.

    Pericor researchers believe this development could result in a drug for interventional cardiology that will prevent thrombosis and restenosis and not retard healing of the blood vessel. Restenosis is the re-narrowing of a coronary artery after it has been treated with angioplasty or stenting.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?